Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about OVID, unsubscribe in one click. Privacy
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| Gaboxadol | Primary Disease or Condition Being Studied: Angelman Syndrome (AS) | Phase 3 · NCT04106557 | Completed |
| OV101 | Fragile X Syndrome (FXS) | Phase 2 · NCT03697161 | Completed |
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
OVID holds $161.4M in cash and short-term investments (as of Sep 30, 2026) and burns about $16.7M/quarter from operations, an estimated runway of 28.9 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure: 45 · Elevated
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when OVID files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| Sirenia Capital Management LP | Institution (13G, 5%+) | 18,031,333 | 9.55% | 2026-03-31 |
| RA Capital Management, L.P. | Institution (13G, 5%+) | 15,968,626 | 8.46% | 2026-09-30 |
| Affinity Asset Advisors, LLC | Institution (13G, 5%+) | 15,143,728 | 8.02% | 2026-06-30 |
| Eventide Asset Management, LLC | Institution (13G, 5%+) | 11,812,241 | 6.26% | 2026-06-30 |
| BlackRock, Inc. | Institution (13G, 5%+) | 10,822,672 | 5.73% | 2026-06-30 |
| TAKEDA PHARMACEUTICAL CO LTD 10% owner |
Insider | 8,781,996 | 4.65% | 2025-12-08 |
| JANUS HENDERSON GROUP PLC | Institution (13G, 5%+) | 7,114,114 | 3.77% | 2025-11-28 |
| Jeremy M Levin Executive Chairman, Director · +2.69M options |
Insider | 3,770,509 | 2.00% | 2026-03-23 |
| Stelios Papadopoulos Director · +155,000 options |
Insider | 217,578 | 0.12% | 2026-04-07 |
| Jeffrey A Rona CBFO · +986,250 options |
Insider | 156,313 | 0.08% | 2026-02-23 |
| Charles Ross Carter Chief Financial Officer |
Insider | 94,375 | 0.05% | 2026-07-06 |
| Margaret A. Alexander President and CEO, Director · +2.73M options |
Insider | 61,750 | 0.03% | 2026-02-23 |
Share count 188,731,914 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for OVID and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →